0000950123-21-015534.txt : 20211115 0000950123-21-015534.hdr.sgml : 20211115 20211115160840 ACCESSION NUMBER: 0000950123-21-015534 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211115 DATE AS OF CHANGE: 20211115 EFFECTIVENESS DATE: 20211115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bain Capital Life Sciences Investors, LLC CENTRAL INDEX KEY: 0001703031 IRS NUMBER: 813996001 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-18477 FILM NUMBER: 211410529 BUSINESS ADDRESS: STREET 1: 200 CLARENDON STREET CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6175162878 MAIL ADDRESS: STREET 1: 200 CLARENDON STREET CITY: BOSTON STATE: MA ZIP: 02116 13F-HR 1 primary_doc.xml 13F-HR LIVE 0001703031 XXXXXXXX 09-30-2021 09-30-2021 false Bain Capital Life Sciences Investors, LLC

200 Clarendon Street Boston MA 02116

13F HOLDINGS REPORT 028-18477 Y Bain Capital Life Sciences Investors, LLC is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P., (ii) the general partner of BC SW, LP and (iii) the manager of Bain Capital Life Sciences Investors II, LLC, which is the general parter of Bain Capital Life Sciences Fund II, L.P. The shares of common stock of Savara Inc ("SVRA") included on the Information Table are as reported on Amendment No. 1 to the Schedule 13D filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on March 17, 2021 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of SVRA common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding SVRA common stock following such exercise or conversion. As of September 30, 2021, such persons held an aggregate of 6,913,208 shares of SVRA common stock. The shares of common stock of Syros Pharmaceuticals, Inc. ("SYRS" ) included on the Information Table are as reported on the Schedule 13G filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on December 14, 2020 and reflect the exercise and conversion, as applicable, of securities convertible into or exercisable for shares of SYRS common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise or conversion of such securities if such persons would beneficially own more than 9.99% of the outstanding SYRS common stock following such exercise or conversion. As of September 30, 2021, such persons held an aggregate of 5,504,661 shares of SYRS common stock. Adam Koppel 617-516-2000 /s/ Adam Koppel Boston MA 11-15-2021 5 33 1612006 false 1 28-18476 Bain Capital Life Sciences Partners, LP 2 28-18478 Bain Capital Life Sciences Fund, L.P. 3 28-20270 BC SW, LP 4 28-20816 Bain Capital Life Sciences Investors II, LLC 5 28-20814 Bain Capital Life Sciences Fund II, L.P. INFORMATION TABLE 2 7412.xml INFORMATION TABLE FOR FORM 13F DICERNA PHARMACEUTICALS INC COM 253031108 62098 3080237 SH SOLE 3080237 0 0 MARINUS PHARMACEUTICALS INC COM NEW 56854Q200 16285 1431058 SH SOLE 1431058 0 0 SOLID BIOSCIENCES INC COM 83422E105 18953 7929918 SH SOLE 7929918 0 0 APTINYX INC COM 03836N103 20807 8891758 SH SOLE 8891758 0 0 SPRINGWORKS THERAPEUTICS INC COM 85205L107 306498 4831307 SH SOLE 4831307 0 0 DYNAVAX TECHNOLOGIES CORP COM NEW 268158201 161652 8415000 SH SOLE 8415000 0 0 X4 PHARMACEUTICALS INC COM 98420X103 11212 2119540 SH SOLE 2119540 0 0 SAVARA INC COM 805111101 16039 11622598 SH SOLE 11622598 0 0 ARCUTIS BIOTHERAPEUTICS INC. COM 03969K108 95065 3979292 SH SOLE 3979292 0 0 MERSANA THERAPEUTICS INC. COM 59045L106 34850 3695667 SH SOLE 3695667 0 0 CRINETICS PHARMACEUTICALS COM 22663K107 35358 1679701 SH SOLE 1679701 0 0 AEGLEA BIO THERAPEUTICS INC COM 00773J103 22639 2847689 SH SOLE 2847689 0 0 ANNEXON INC COM 03589W102 60327 3241628 SH SOLE 3241628 0 0 NURIX THERAPEUTICS INC COM 67080M103 38478 1284314 SH SOLE 1284314 0 0 RAPID MICRO BIOSYSTEMS INC CLASS A COM 75340L104 155786 8434560 SH SOLE 8434560 0 0 RESEARCH ALLIANCE CORP II COM CL A 760873109 9850 1000000 SH SOLE 1000000 0 0 NAUTILUS BIOTECHNOLOGY INC COM 63909J108 12280 2000000 SH SOLE 2000000 0 0 TANGO THERAPEUTICS INC COM 87583X109 24849 1921790 SH SOLE 1921790 0 0 SYROS PHARMACEUTICALS INC COM 87184Q107 25859 5785036 SH SOLE 5785036 0 0 ATEA PHARMACEUTICALS INC COM 04683R106 129722 3700000 SH SOLE 3700000 0 0 C4 THERAPEUTICS INC COM STK 12529R107 73374 1642209 SH SOLE 1642209 0 0 BCLS ACQUISITION CORP COM CL A G0904B105 4856 487500 SH SOLE 487500 0 0 JIYA ACQUISITION CORP COM CL A 47760M102 2925 300000 SH SOLE 300000 0 0 HELIX ACQUISITION CORP COM CL A G4444C102 2488 250000 SH SOLE 250000 0 0 FRAZIER LIFESCIENCES ACQU CO UNIT 12/09/2025 G3710A121 3009 300000 SH SOLE 300000 0 0 PHARVARIS N V COM N69605108 56392 3180601 SH SOLE 3180601 0 0 ARYA SCIENCES ACQU CORP IV CL A G31659108 7035 700000 SH SOLE 700000 0 0 PANACEA ACQUISITION CORP II CL A SHS G6882C106 4885 500000 SH SOLE 500000 0 0 BLUEBIRD BIO INC COM 09609G100 7239 538179 SH SOLE 538179 0 0 OMEGA ALPHA SPAC CL A G6749V107 3894 400000 SH SOLE 400000 0 0 NUVALENT INC COM 670703107 77302 3428014 SH SOLE 3428014 0 0 ADAGIO THERAPEUTICS INC COM 00534A102 105060 2487207 SH SOLE 2487207 0 0 ARYA SCIENCES ACQUISITN CORP CLASS A ORD SHS G31658100 4940 500000 SH SOLE 500000 0 0